Details for New Drug Application (NDA): 213082
✉ Email this page to a colleague
The generic ingredient in XELJANZ is tofacitinib citrate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.
Summary for 213082
Tradename: | XELJANZ |
Applicant: | Pfizer |
Ingredient: | tofacitinib citrate |
Patents: | 1 |
Pharmacology for NDA: 213082
Mechanism of Action | Janus Kinase Inhibitors |
Suppliers and Packaging for NDA: 213082
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
XELJANZ | tofacitinib citrate | SOLUTION;ORAL | 213082 | NDA | Pfizer Laboratories Div Pfizer Inc | 0069-1029 | 0069-1029-02 | 1 BOTTLE in 1 CARTON (0069-1029-02) / 240 mL in 1 BOTTLE (0069-1029-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | EQ 1MG BASE/ML | ||||
Approval Date: | Sep 25, 2020 | TE: | RLD: | Yes | |||||
Patent: | RE41783 | Patent Expiration: | Dec 8, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? |
Expired US Patents for NDA 213082
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer | XELJANZ | tofacitinib citrate | SOLUTION;ORAL | 213082-001 | Sep 25, 2020 | 6,956,041 | ⤷ Subscribe |
Pfizer | XELJANZ | tofacitinib citrate | SOLUTION;ORAL | 213082-001 | Sep 25, 2020 | 7,301,023 | ⤷ Subscribe |
Pfizer | XELJANZ | tofacitinib citrate | SOLUTION;ORAL | 213082-001 | Sep 25, 2020 | 7,265,221 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription